Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690479 | 0.91 | KCNQ2 (0.45) | TAS1R3TAS1R1TAS1R2DPP9DPP4 | |
| SCHEMBL19690561 | 0.91 | KCNQ2 (0.41) | TAS1R3TAS1R1TAS1R2DPP9DPP4 | |
| SCHEMBL19690462 | 0.86 | L3MBTL1 (0.40) | DPP7KCNQ2NAMPT | |
| SCHEMBL19698447 | 0.86 | KCNQ2 (0.53) | DPP9DPP4DPP8DPP7KCNQ2 | |
| SCHEMBL30741292 | 0.86 | KCNQ2 (0.53) | DPP9DPP4DPP8DPP7KCNQ2 | |
| SCHEMBL19698503 | 0.81 | KCNQ2 (0.45) | TAS1R3TAS1R1TAS1R2DPP9DPP4 | |
| SCHEMBL19690570 | 0.79 | HDAC3 (0.49) | TAS1R3TAS1R1TAS1R2DPP9DPP4 | |
| SCHEMBL19690590 | 0.78 | NOTUM (0.41) | DPP7KCNQ2 | |
| SCHEMBL26973820 | 0.78 | KCNQ2 (0.47) | TAS1R3TAS1R1TAS1R2DPP9DPP4 | |
| SCHEMBL19690564 | 0.78 | NOTUM (0.41) | DPP7KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | OCUTERRA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210309612-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | OCUTERRA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| EP-3468947-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | SciFluor Life Sciences, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214539-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355679-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | SCIFLUOR LIFE SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355679-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | KCNQ2, KCNQ1, KCNQ3 | TAS1R3 1250/4885TAS1R1 3160/4885TAS1R2 2130/4885 |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | KCNQ2, KCNQ1, KCNQ3 | TAS1R3 1250/4885TAS1R1 3160/4885TAS1R2 2130/4885 |
| US-20210309612-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | KCNQ2, KCNQ1, KCNQ3 | TAS1R3 1250/4885TAS1R1 3160/4885TAS1R2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.